Eisai Ltd., of Hatfield, UK, said women with locally advanced or metastatic breast cancer (MBC) in Russia will have earlier access to Halaven (eribulin), indicated for patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease.